Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B

The findings supporting bepirovirsen were deemed a “historic moment” by physicians and validate a drug that has “clear blockbuster potential,” according to one analyst.

An experimental GSK drug helped 1 in 5 patients with chronic hepatitis B achieve what's known as a functional cure, vastly outpacing current treatments.

GSK has shared detailed results from a pair of late-stage trials testing a chronic hepatitis B treatment originally developed by Ionis Pharmaceuticals, with regulatory reviews…

GSK's experimental hepatitis B drug, bepirovirsen, showed promising results in late-stage studies, with nearly one in five patients achieving a functional cure after six months of…

Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B

New research suggests a first-of-its-kind drug for hepatitis B may let some patients stop treatment without showing signs of the dangerous liver virus

Tratamentos atuais proporcionam cura para apenas cerca de 1% das pessoas que vivem com o vírus de forma crônica

Findings 'will change the landscape' of treatment, researcher says

In an editorial published in the New England Journal of Medicine, University of Michigan Health hepatologist Anna S. Lok, M.D., hails newly announced results of the B-Well…

Across two large trials, roughly 20% of people treated with bepirovirsen had undetectable levels of the virus after stopping all treatment.